Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (DE:AMG)
XETRA:AMG
Amgen (AMG) Stock Price & Analysis
8 Followers
AMG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€190.63 - €301.46
Previous Close€288.65
Volume1.00
Average Volume (3M)588.00
Market Cap
€155.46B
Enterprise Value€205.65B
Total Cash (Recent Filing)$9.71B
Total Debt (Recent Filing)$64.02B
Price to Earnings (P/E)44.8
Beta0.20
Next Earnings
Jul 30, 2024EPS Estimate
€4.58Last Dividend Ex-Date
May 16, 2024Dividend Yield2.71%
Share Statistics
EPS (TTM)6.44
Shares Outstanding536,434,692
10 Day Avg. Volume1,221
30 Day Avg. Volume588
Standard Deviation0.07
R-Squared0.10
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.72
Price to Sales (P/S)20.79
Price to Cash Flow (P/CF)60.60
P/FCF Ratio22.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.96
Enterprise Value/Gross Profit10.42
Enterprise Value/Ebitda16.89
Forecast
1Y Price Target
€296.46Price Target Upside6.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
Bulls Say, Bears Say
Bulls Say
Drug ApprovalFDA announced accelerated approval of Imdelltra (tarlatamab) in advanced SCLC, highlighting Amgen's potential to boost sales with this new treatment option.
Financial PerformanceAmgen's shares surged on the news of a positive interim update from the MariTide study in obesity, signaling strong market confidence in the company's pipeline.
Pipeline DevelopmentManagement's commitment to advancing MariTide into phase 3 trials for obesity and related conditions, as well as phase 2 for diabetes, showcases Amgen's proactive strategy in addressing diverse medical needs.
Bears Say
Clinical Data TransparencyFinancials were ok but the punchline came in management's encouraging characterization of MariTide interim Phase 2 data, although no data were actually provided.
Financial PerformanceProduct sales came in about $100MM light, driven by weak sales in several key products.
Product ChallengesLogistics with Imdelltra are not trivial, including requirements such as 1 hour infusion, 22-24 hour monitoring for first two treatments, and remaining within 1 hour of healthcare setting for 48 hours for first two infusions.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
21.40% Mutual Funds
43.23% Other Institutional Investors
34.29% Public Companies and
Individual Investors
AMG FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was €190.63 and its highest was €301.46 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Jul 30, 2024 which is in 74 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on May 02, 2024. The company reported €3.647 earnings per share for the quarter, beating the consensus estimate of €3.572 by €0.075.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of €2.08 which represents an annual dividend yield of 2.71%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is €4.58.
How many shares outstanding does Amgen have?
Amgen has 536,434,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of €3.647 in its last earnings report, beating expectations of €3.572. Following the earnings report the stock price went up 13.632%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€296.46 (6.20% Upside)
€296.46 (6.20% Upside)
Blogger Sentiment
Bullish
DE:AMG Sentiment 88%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.76%
12-Months-Change
Fundamentals
Return on Equity
72.57%
Trailing 12-Months
Asset Growth
4.80%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMG Company Deck
---
AMG Earnings Call
Q1 2024
0:00 / 0:00
---
AMG Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMG Stock 12 Month Forecast
Average Price Target
€296.46
▲(6.20% Upside)
Technical Analysis
Best Analysts Covering AMG
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+16.92%
reiterated a buy rating 15 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +16.92% per trade.
---